PXVX 0047
Alternative Names: adenovirus 4/7 vaccine; Adenovirus Type 4 and Type 7 Vaccine [A549 Cells] - PaxVax; Adenovirus Vaccines - Emergent BioSolutions; ADVV-MP; Modernized Production Adenovirus Vaccine - PaxVax; MPAV Prototype A; MPAV Prototype B; PXVX0047; pxvx0047 vaccineLatest Information Update: 31 Oct 2021
At a glance
- Originator PaxVax
- Developer PaxVax; Walter Reed Army Institute of Research
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Adenovirus infections
Most Recent Events
- 01 Jul 2019 Discontinued - Phase-I for Adenovirus infections (In volunteers) in USA (PO) (Emergent Biosolutions pipeline, July 2019)
- 01 Jul 2019 Discontinued - Preclinical for Adenovirus infections in USA (PO) (Emergent Biosolutions pipeline, July 2019)
- 04 Oct 2018 PaxVax has been acquired by Emergent BioSolutions